20 articles
GlaxoSmithKline tests a novel NS5B inhibitor across four dose groups in chronic HCV patients, evaluating safety and short-term antiviral activity.
Scientists discover unique immune peptide patterns in Behçet's disease patients that trigger harmful inflammation responses.
A completed Phase 3 trial tests placental MSC secretome injections against placebo in 60 GvHD patients at an Iranian hospital.
New research reveals how immune cells use cysteine for both antioxidant defense and energy production, with major implications for cancer treatment.
A newly identified protein, SCARF2, acts as an internal escort for HBV, transporting the virus from the cytoplasm to the nuclear pore β a potential new drug target.
Specialized immune cells use antibodies to kill hepatitis B-infected cells, offering new targets for viral cure strategies.
A newly identified immune axis involving CD16+ Ξ³Ξ΄ T cells and antibody-dependent killing may reshape how we understand HBV immune control.
New research reveals how a mitochondrial enzyme enhances immune cell function to fight bacterial lung infections and reduce inflammation.
Structural biology uncovers the exact amino acid motif causing species-specific drug failures, enabling transgenic mouse models for better P2X7 drug testing.
A new in vitro study shows Thymosin Ξ±1 triggers dendritic cells to release IL-15, boosting CD8+ T cell killing and reducing HIV reservoir size.
New research reveals how granzyme A protein targets specific cells for pyroptosis, a form of programmed cell death crucial for immune defense.
A randomized trial shows prophylactic obinutuzumab dramatically reduces steroid-requiring cGVHD after bone marrow transplant.
New research reveals how hepatitis B virus hijacks cellular machinery to suppress interferon signaling and evade immune detection.
GZMK+CD8+ T cells promote chronic inflammation and aging-related diseaseβa newly recognized immune threat beyond cytotoxicity.
A major review outlines how targeted hematologic therapies are transforming outcomes in MGRS, a rare but serious cause of kidney injury.
Researchers modified NK and T cells with special receptors that help them track down and infiltrate solid tumors more effectively.
A completed French trial investigated whether rogue antibodies targeting ghrelin and alpha-MSH disrupt appetite regulation in eating disorder patients.
Dying cancer cells release GPX4 protein that prevents immune system activation, revealing new immunotherapy targets.
Senescent cells drive cyst growth in ADPKD, and targeting them with senolytics or the aldose reductase inhibitor epalrestat delays disease progression.
New research reveals efgartigimod reshapes B-cell populations in myasthenia gravis, inducing regulatory plasma cells linked to clinical improvement.
